If that happens, well update this guide accordingly and continue pointing you to the best pathways to prescription access
GLP-1RAs, which increase satiety and reduce hunger and increasing satiety could exacerbate dietary restriction (i.e., physiological undereating) and dietary restraint (i.e., the cognitive effort to reduce food intake) by encouraging the adoption of extreme and rigid dietary rules (see Figure 1)
the science is similar, but the marketing language and price points differ .[26][10][8] This allows differential pricing and targeted campaigns: employers, payers and governments may pay more for weightloss or cardioprotective positioning than for plain glucose control.[18][15] 5.3 Patent Fences and Legal Strategy Around the original patent, firms file patents on pens, dosing regimens, combinations and small formulation changes, creating a thicket that generic manufacturers must fight through.[27][14] In evergreeningfriendly countries, this can delay generics by years
Should Phase 3 trials demonstrate a favourable benefit-risk profile, Eli Lilly would be expected to submit a Marketing Authorisation Application (MAA) to the MHRA (and separately to the EMA for European markets) for regulatory review
